Trial Profile

Apixaban in the Prevention of Stroke and Systemic Embolism in Patients With Atrial Fibrillation in Real-Life Setting in France - Cross-sectional Study

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 02 Jan 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Apixaban (Primary) ; Dabigatran etexilate; Rivaroxaban; Vitamin K antagonists
Indications Embolism; Stroke
Focus Therapeutic Use
Acronyms PAROS
Sponsors Bristol-Myers Squibb

Most Recent Events

28 Mar 2017 Status changed from active, no longer recruiting to completed.
27 Oct 2016 Status changed from recruiting to active, no longer recruiting.
12 Apr 2016 Planned End Date changed from 1 Sep 2016 to 1 Jan 2017 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com